Skip to content
CNS Clinical Research

Boston, Massachusetts

CNS clinical trials in Boston, MA

153 CNS studies are recruiting participants at sites in Boston as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 153 studies are recruiting at a site in Boston.
  • By phase: Early Phase 1 (1), Phase 1 (5), Phase 1/2 (6), Phase 2 (12), Phase 2/3 (1), Phase 3 (30), Phase 4 (11), No phase (60), Observational (27). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (98), industry (52), government (3).
  • By research area: Depression (66), Parkinson's Disease (23), Epilepsy (22), Multiple Sclerosis (18), Schizophrenia (11), ADHD (8), Migraine (5).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 153). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Adams Clinical Boston
    Registry record
    NCT06793397 · updated
  2. Longitudinal Assessment of Biomarkers Among Patients With MDD

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study site
    Depression Clinical Research Program
    Registry record
    NCT07931001 · updated
  3. Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT05450432 · updated
  4. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT07002034 · updated
  5. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  6. Time Restricted Eating (TRE) in Bipolar Disorder

    • No phase
    • Ages 18 to 65
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07211217 · updated
  7. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Adams Clinical Watertown
    Registry record
    NCT07592689 · updated
  8. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study site
    Massachusetts General Hospital
    Registry record
    NCT03887715 · updated
  9. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT06748222 · updated
  10. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Adams Clinical Boston
    Registry record
    NCT07412756 · updated
  11. TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

    • Observational
    • From 18 months, up to 11 years
    • All sexes
    Sponsor
    State University of New York at Buffalo
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07048574 · updated
  12. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Boston Childrens Hospital
    Registry record
    NCT07227454 · updated
  13. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Adams Clinical Boston
    Registry record
    NCT07573176 · updated
  14. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Adams Clinical Boston
    Registry record
    NCT07775300 · updated
  15. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Boston, MA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Boston

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Boston Children's Hospital
    Registry record
    NCT07288567 · updated
  2. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Boston Children's Hospital
    Registry record
    NCT07424404 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Boston, MA on ClinicalTrials.gov.

ADHD studies recruiting in Boston

  1. The Myelin Disorders Biorepository Project

    • Observational
    • All ages
    • All sexes
    Sponsor
    Children's Hospital of Philadelphia
    Study site
    Massachusetts General Hospital (MGH)
    Registry record
    NCT03047369 · updated
  2. National Pregnancy Registry for Psychiatric Medications

    • Observational
    • Ages 18 to 45
    • Female participants
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT01246765 · updated
  3. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Boston Clinical Trials
    Registry record
    NCT07759154 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Boston, MA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Boston

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Tufts Medical Center ( Site 6052)
    Registry record
    NCT06952504 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Dana Farber Cancer Institute ( Site 0090) · Massachusetts General Hospital Cancer Center ( Site 0091)
    Registry record
    NCT06966700 · updated
  4. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Dana Farber Cancer Hospital ( Site 0155) · Massachusetts General Hospital ( Site 0136)
    Registry record
    NCT06623422 · updated
  5. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    Massachusetts General Hospital
    Registry record
    NCT06996652 · updated
  6. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07174310 · updated
  7. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study sites
    Beth Israel Deaconess Medical Center · Tufts Medical Center - Neurology
    Registry record
    NCT06944522 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Boston, MA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Boston

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital Cancer Center
    Registry record
    NCT03816345 · updated
  2. Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    • Phase 3
    • Ages 25 to 75
    • All sexes
    Sponsor
    MGH Institute of Health Professions
    Study site
    MGH Institute of Health Professions
    Registry record
    NCT06136728 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Boston, MA on ClinicalTrials.gov.

Epilepsy studies recruiting in Boston

  1. Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    Registry record
    NCT04419272 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call